missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ IGF1R (CD221) Biosimilar Recombinant Monoclonal Antibody

Descripción
For reconstitution, add sterile, distilled water to achieve a final antibody concentration of 1 mg/mL. Gently shake to solubilize the protein completely. Do not vortex. Reconstituted products should be stored at -80 °. This antibody can also be cross referenced by the term Immunomedics patent anti-IGF-1R.
IGF1R, also known as Insulin-like Growth Factor 1 (IGF-1) Receptor, is a receptor tyrosine kinase activated by IGF-1 and IGF-2. IGFR has been implicated in a variety of cancers. The protein is a tetramer consisting of two alpha, and two beta subunits. The alpha-subunits binds to insulin growth factor 1 with higher affinity than to insulin growth factor 2. Binding results in a conformational change, followed by autophosphorylation of IGF-1R at positions 1134, 1135, 1136. The activated IGF-1R in turn, causes phosphorylation of substrate proteins, followed by sequential activation of RAS, RAF, and mitogen-activated protein kinase isoforms ERK, p38, and JNK, leading to the transcription of genes that drive proliferation.
Especificaciones
Especificaciones
| Antígeno | IGF1R (CD221) Humanized Biosimilar |
| Aplicaciones | ELISA, Flow Cytometry, Functional Assay, Surface Plasmon Resonance |
| Clasificación | Recombinant Monoclonal |
| Concentración | 1 mg/mL |
| Conjugado | Unconjugated |
| Formulación | 25mM histidine with 8% sucrose, 0.01% Tween 80 and no preservative; pH 6.2 |
| Especie del huésped | Human |
| Método de purificación | Protein A |
| Cantidad | 100 μg |
| Estado normativo | RUO |
| Mostrar más |
Título del producto
Al hacer clic en Enviar, acepta que Fisher Scientific se ponga en contacto con usted en relación con los comentarios que ha proporcionado en este formulario. No compartiremos su información para ningún otro fin. Toda la información de contacto proporcionada se mantendrá de acuerdo con nuestra Política de Privacidad. Política de privacidad.
¿Detecta una oportunidad de mejora?